**Supplement table no. 2: Course of disease case no 2**

|  |  |  |  |
| --- | --- | --- | --- |
| **Year** | **Date** | **Therapy** | **Staging** |
| **2005** | 01/2005 |  | Initial diagnosis of a NET G2 of the right kidneysynaphtophysin +, chromogranin +, NSE +, vimentin +, S 100+CD7-Ki-67 5% |
|  | 01/2005 | right nephrectomy |  |
| **2007** | 08/2007 | lymphadenectomy | Lymph node metastases |
| **2010** | 02/2010 |  |  |
|  | 04/2010 | retrocaval tumor with partial resection of the Vena Cava inferior, lymphadenectomy | Ki-67 up to 20% |
|  | 09/2010 |  | Initial diagnosis of SSR positive liver and SSR negative pulmonal metastases |
|  | 09/2010 – 03/2013 | SSA (octreotide) |  |
| **2012** | 02/2012 |  | SD |
|  | 04/2012 |  | PD, initial diagnosis of bone metastases |
| **2012** | 04 – 12/2012 | everolimus + SSA (octreotide) |  |
|  | 12/2012 |  | PD |
|  | 04/2013-01/2016 | PRRT Lut-177-DOTATATE (3 cycles) |  |
|  | 11/2014 – 01/2018 | TAE (5 cycles) |  |
| **2015** | 10/2015 |  | PD |
| **2016** | 06/2016-09/2017 | CAP/TEM |  |
| **2017** | 09/2017 |  | PD |
|  | 05/2018 – 06/2018 | SIRT (2 cycles) |  |
| **2018** | 08/2018 |  | PR |
| **2019** | 01/2019 | afterloading + biopsy | PD-L1 1%No MMR deficiency |
|  | 08/2019 |  | PD |
|  |  | pembrolizumab |  |
| **2020** | 02/2020 |  | PR |

neuroendocrine tumor (NET), partial remission (PR), progressive disease (PD), stable disease (SD), peptide receptor radionuclide therapy (PRRT), mismatch- repair (MMR), transarterial embolization (TAE), somatostatin analogue (SSA), selective internal radiation therapy (SIRT)